FDA Revisits Wellbutrin Generics – Again; Will Teva Fund A High-Dose Study?

As FDA considers how best to address continued concerns about generics for Wellbutrin XL (bupropion extended-release tablets), one issue it may wrestle with is whether it should conduct bioequivalence studies at the highest dose, 300 mg, which has a higher risk of seizures

More from Archive

More from Pink Sheet